NASDAQ:HOOK - Nasdaq - US43906K2096 - Common Stock - Currency: USD
NASDAQ:HOOK (3/7/2025, 8:00:01 PM)
1.27
-0.03 (-2.31%)
The current stock price of HOOK is 1.27 USD. In the past month the price decreased by -33.16%. In the past year, price decreased by -83.31%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
HOOKIPA Pharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 151 full-time employees. The company went IPO on 2019-04-18. HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
HOOKIPA PHARMA INC
350 Fifth Avenue, 72Nd Floor, Suite 7240
New York City NEW YORK 10118 US
CEO: Joern Aldag
Employees: 165
Company Website: https://www.hookipapharma.com/
Investor Relations: https://ir.hookipapharma.com/
Phone: 114318906360
The current stock price of HOOK is 1.27 USD. The price decreased by -2.31% in the last trading session.
The exchange symbol of HOOKIPA PHARMA INC is HOOK and it is listed on the Nasdaq exchange.
HOOK stock is listed on the Nasdaq exchange.
9 analysts have analysed HOOK and the average price target is 25.25 USD. This implies a price increase of 1887.8% is expected in the next year compared to the current price of 1.27. Check the HOOKIPA PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HOOKIPA PHARMA INC (HOOK) has a market capitalization of 15.32M USD. This makes HOOK a Nano Cap stock.
HOOKIPA PHARMA INC (HOOK) currently has 165 employees.
HOOKIPA PHARMA INC (HOOK) has a resistance level at 1.83. Check the full technical report for a detailed analysis of HOOK support and resistance levels.
The Revenue of HOOKIPA PHARMA INC (HOOK) is expected to grow by 160.99% in the next year. Check the estimates tab for more information on the HOOK EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HOOK does not pay a dividend.
HOOKIPA PHARMA INC (HOOK) will report earnings on 2025-03-20, after the market close.
HOOKIPA PHARMA INC (HOOK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.72).
The outstanding short interest for HOOKIPA PHARMA INC (HOOK) is 1.11% of its float. Check the ownership tab for more information on the HOOK short interest.
ChartMill assigns a fundamental rating of 4 / 10 to HOOK. While HOOK has a great health rating, there are worries on its profitability.
Over the last trailing twelve months HOOK reported a non-GAAP Earnings per Share(EPS) of -3.72. The EPS increased by 55.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -39.53% | ||
ROE | -60.4% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to HOOK. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 81.65% and a revenue growth 160.99% for HOOK